8-K Announcements
6Material company update
May 14, 2026·SEC
Material company update
May 12, 2026·SEC
Material company update
May 7, 2026·SEC
Gyre Therapeutics, Inc.(GYRE)Earnings, Financials & Key Ratios
GYRE•NASDAQ
277.8× P/E·Price updated Jun 19, 2026
AboutGyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease. The company is also involved the development of F351 (Hydronidone), a structural derivative of ETUARY (Pirfenidone), under Phase 3 studies for the treatment of chronic hepatitis B liver fibrosis; and under Phase 1 studies for liver fibrosis associated with nonalcoholic associated steatohepatitis. In addition, its development pipeline includes F573, under Phase 2 studies for the treatment of acute/acute-on-chronic liver failure; F528, under preclinical stage for the treatment of chronic obstructive pulmonary disease; and F230, under preclinical stage for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.Show more
- Revenue$117M+10.2%
- EBITDA$14M-21.1%
- Net Income$5M-58.4%
- EPS (Diluted)0.02-55.0%
- Gross Margin95.35%-1.0%
- EBITDA Margin12.02%-28.4%
- Operating Margin9.86%-35.5%
- Net Margin4.31%-62.3%
- ROE4.18%-80.6%
GYRE Key Insights
Gyre Therapeutics, Inc. (GYRE) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Strong 5Y sales CAGR of 41.0%
✗Weaknesses
- ✗Negative free cash flow
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when GYRE posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
GYRE Price & Volume
Gyre Therapeutics, Inc. (GYRE) stock price & volume — 10-year historical chart
Loading chart...
GYRE Growth Metrics
Gyre Therapeutics, Inc. (GYRE) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years52.18%
5 Years40.96%
3 Years4.46%
TTM16.3%
Profit CAGR
10 Years-
5 Years-
3 Years29.74%
TTM-186.71%
EPS CAGR
10 Years-
5 Years-
3 Years-9.14%
TTM-8.89%
Return on Capital
10 Years-54.14%
5 Years-35.93%
3 Years-18.18%
Last Year9.06%
GYRE Recent Earnings
Gyre Therapeutics, Inc. (GYRE) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 2/12 qtrs (22%)●Beat Revenue 2/12 qtrs (29%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.05+16.7%
$0.06
Rev
$23M-28.8%
$32M
Q2 2026
Mar 12, 2026Metric
Actual
Est
EPS
$0.04-29.4%
$0.06
Rev
$37M+5.0%
$35M
Q4 2025
Nov 7, 2025Metric
Actual
Est
EPS
$0.06+20.0%
$0.05
Rev
$31M-15.8%
$36M
Q3 2025
Aug 11, 2025Metric
Actual
Est
EPS
$0.02-33.3%
$0.03
Rev
$27M-22.0%
$34M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.05vs $0.06+16.7% | $23Mvs $32M-28.8% |
| Q2 2026 | Mar 12, 2026 | $0.04vs $0.06-29.4% | $37Mvs $35M+5.0% |
| Q4 2025 | Nov 7, 2025 | $0.06vs $0.05+20.0% | $31Mvs $36M-15.8% |
| Q3 2025 | Aug 11, 2025 | $0.02vs $0.03-33.3% | $27Mvs $34M-22.0% |
Based on last 12 quarters of dataView full earnings history →
GYRE Peer Comparison
Gyre Therapeutics, Inc. (GYRE) competitors in Immunology and Inflammation Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 HALO | 8.13B | 68.55 | 26.78 | 37.55% | 23.13% | 126.27% | 43.89 | |
 ARDX | 1.48B | 6.05 | -23.27 | 22.09% | -13.58% | -38.11% | 1.27 | |
 PRAX | 8.15B | 282.31 | -20.94 | -100% | -43.02% | 0.00 | ||
 ACAD | 3.7B | 21.62 | 9.44 | 11.87% | 34.3% | 35.65% | 0.04 | |
 INVA | 1.66B | 22.49 | 6.82 | 18.52% | 118.91% | 47.59% | 0.23 | |
 IDYA | 2.74B | 31.23 | -24.40 | 30.24% | -62.17% | -13.96% | 0.03 | |
 RCUS | 2.45B | 24.31 | -7.39 | -4.26% | -156.36% | -68.97% | 0.16 | |
 TGTX | 8.15B | 53.22 | 19.21 | 87.32% | 65.95% | 87.36% | 0.40 |
Compare GYRE vs Peers
Gyre Therapeutics, Inc. (GYRE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
GYRE Income Statement
Gyre Therapeutics, Inc. (GYRE) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 1.02M | 6K | 0 | 20.95M | 7.34M | 102.29M | 113.45M | 105.76M | 116.59M | 117.05M |
Revenue Growth % | 155.14% | -99.41% | -100% | - | -64.97% | 1293.98% | 10.91% | -6.78% | 10.24% | 16.3% |
Cost of Goods Sold | 12.85M | 21.47M | 146K | 9.16M | 7.67M | 4.79M | 4.64M | 3.88M | 5.42M | 5.75M |
COGS % of Revenue | 1261.98% | 357900% | - | 43.74% | 104.52% | 4.69% | 4.09% | 3.67% | 4.65% | - |
Gross Profit | -11.83M▲ 0% | -21.47M▼ 81.5% | -146K▲ 99.3% | 11.79M▲ 8171.9% | -332K▼ 102.8% | 97.5M▲ 29466.6% | 108.81M▲ 11.6% | 101.87M▼ 6.4% | 111.17M▲ 9.1% | 111.3M▲ 0% |
Gross Margin % | -1161.98% | -357800% | - | 56.26% | -4.52% | 95.31% | 95.91% | 96.33% | 95.35% | 95.09% |
Gross Profit Growth % | -16.47% | -81.49% | 99.32% | 8171.92% | -102.82% | 29466.57% | 11.61% | -6.38% | 9.13% | - |
Operating Expenses | 22.84M | 33.83M | 57.13M | 69.16M | 83.39M | 88.29M | 176.04M | 85.71M | 99.68M | 111.44M |
OpEx % of Revenue | 2243.61% | 563800% | - | 330.13% | 1136.47% | 86.32% | 155.17% | 81.04% | 85.5% | - |
Selling, General & Admin | 9.99M | 12.35M | 13.27M | 16.18M | 18.82M | 71.61M | 75.82M | 73.62M | 85.98M | 91.54M |
SG&A % of Revenue | 981.63% | 205900% | - | 77.24% | 256.47% | 70% | 66.83% | 69.61% | 73.75% | - |
Research & Development | 12.85M | 21.47M | 43.86M | 52.98M | 64.57M | 16.69M | 13.78M | 12.02M | 13.7M | 17.34M |
R&D % of Revenue | 1261.98% | 357900% | - | 252.89% | 879.99% | 16.31% | 12.15% | 11.37% | 11.75% | - |
Other Operating Expenses | 261K | 1.65M | 0 | 0 | 0 | 0 | 86.44M | 66K | 0 | 1M |
Operating Income | -21.82M▲ 0% | -33.82M▼ 55.0% | -57.28M▼ 69.3% | -57.37M▼ 0.2% | -83.73M▼ 45.9% | 9.2M▲ 111.0% | -67.23M▼ 830.5% | 16.16M▲ 124.0% | 11.49M▼ 28.9% | -139K▲ 0% |
Operating Margin % | -2143.61% | -563700% | - | -273.87% | -1140.99% | 9% | -59.26% | 15.28% | 9.86% | -0.12% |
Operating Income Growth % | -6.88% | -54.99% | -69.35% | -0.16% | -45.94% | 110.99% | -830.52% | 124.04% | -28.91% | - |
EBITDA | -21.65M | -33.67M | -57.13M | -57.23M | -83.44M | 10.33M | -66.12M | 17.75M | 14.01M | 1.85M |
EBITDA Margin % | -2126.62% | -561216.67% | - | -273.21% | -1137.04% | 10.1% | -58.28% | 16.78% | 12.02% | 1.58% |
EBITDA Growth % | -8.09% | -55.54% | -69.66% | -0.18% | -45.79% | 112.38% | -739.91% | 126.85% | -21.07% | -84.72% |
D&A (Non-Cash Add-back) | 173K | 149K | 146K | 138K | 290K | 1.13M | 1.11M | 1.59M | 2.52M | 1.99M |
EBIT | -21.56M | -30.05M | -55.18M | -56.24M | -87.93M | 9.2M | 19.21M | 16.23M | 11.49M | 566K |
Net Interest Income | 0 | 0 | 2.15M | 561K | 39K | 726K | 1.04M | 1.55M | 1.75M | 500K |
Interest Income | 261K | 3.77M | 2.15M | 561K | 39K | 726K | 1.04M | 1.55M | 1.75M | 500K |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | 261K | 3.77M | 2.1M | 1.13M | -4.21M | 209K | -9.73M | 7.05M | 2.94M | 703K |
Pretax Income | -21.56M▲ 0% | -30.05M▼ 39.4% | -55.18M▼ 83.6% | -56.24M▼ 1.9% | -87.93M▼ 56.4% | 9.41M▲ 110.7% | -76.97M▼ 917.7% | 23.22M▲ 130.2% | 14.44M▼ 37.8% | 564K▲ 0% |
Pretax Margin % | -2117.98% | -500916.67% | - | -268.48% | -1198.32% | 9.2% | -67.84% | 21.95% | 12.38% | 0.48% |
Income Tax | -173K | 0 | 0 | -699K | 0 | 5.1M | 8.52M | 5.32M | 4.56M | 3.03M |
Effective Tax Rate % | 0.8% | 0% | 0% | 1.24% | 0% | 54.16% | -11.06% | 22.91% | 31.56% | 537.94% |
Net Income | -21.56M▲ 0% | -30.05M▼ 39.4% | -55.18M▼ 83.6% | -55.54M▼ 0.7% | -87.93M▼ 58.3% | 2.3M▲ 102.6% | -92.93M▼ 4137.1% | 12.09M▲ 113.0% | 5.03M▼ 58.4% | -6.29M▲ 0% |
Net Margin % | -2117.98% | -500916.67% | - | -265.14% | -1198.32% | 2.25% | -81.92% | 11.43% | 4.31% | -5.37% |
Net Income Growth % | -27.24% | -39.4% | -83.59% | -0.66% | -58.32% | 102.62% | -4137.05% | 113% | -58.4% | -186.71% |
Net Income (Continuing) | -21.56M | -30.05M | -55.18M | -55.54M | -87.93M | 4.31M | -85.48M | 17.9M | 9.88M | -2.47M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 29.7M | 29.78M | 35.08M | 36.25M | 35.68M |
EPS (Diluted) | -6.30▲ 0% | -2.68▲ 57.5% | -4.41▼ 64.6% | -2.93▲ 33.6% | -2.87▲ 2.0% | 0.03▲ 101.0% | -1.41▼ 4800.0% | 0.05▲ 103.5% | 0.02▼ 55.0% | -0.07▲ 0% |
EPS Growth % | 71.05% | 57.46% | -64.55% | 33.56% | 2.05% | 101.05% | -4800% | 103.55% | -55% | -8.89% |
EPS (Basic) | -6.30 | -2.68 | -4.41 | -2.93 | -2.87 | 0.03 | -1.41 | 0.14 | 0.06 | - |
Diluted Shares Outstanding | 3.42M | 11.21M | 12M | 19.18M | 30.64M | 75.69M | 65.83M | 102.29M | 103.18M | 91.34M |
Basic Shares Outstanding | 3.42M | 11.21M | 12M | 19.18M | 30.64M | 76.74M | 65.83M | 85.09M | 89.34M | 91.32M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
GYRE Balance Sheet
Gyre Therapeutics, Inc. (GYRE) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 39.11M | 123.99M | 96.07M | 89.51M | 51.48M | 49.65M | 57.22M | 64.79M | 102.37M | 91.73M |
Cash & Short-Term Investments | 32.44M | 120.13M | 76.86M | 79.35M | 46.85M | 25.18M | 33.51M | 26.67M | 52.42M | 37.5M |
Cash Only | 14.47M | 31.21M | 15.37M | 30.36M | 44.35M | 25.18M | 33.51M | 11.81M | 37.07M | 37.5M |
Short-Term Investments | 17.97M | 88.91M | 61.5M | 48.99M | 2.5M | 0 | 0 | 14.86M | 15.36M | 0 |
Accounts Receivable | 24K | 0 | 15M | 3.31M | 1.82M | 15.61M | 16.84M | 29.15M | 36.95M | 22.76M |
Days Sales Outstanding | 8.61 | - | - | 57.73 | 90.43 | 55.72 | 54.18 | 100.62 | 115.67 | 86.49 |
Inventory | 5.31M | 0 | 0 | 0 | 0 | 6.12M | 4.28M | 6.34M | 10.17M | 11.35M |
Days Inventory Outstanding | 150.84 | - | - | - | - | 466.21 | 337.05 | 595.52 | 685.45 | 622.8 |
Other Current Assets | 1.33M | 3.86M | 4.2M | 6.84M | 2.81M | 2.37M | 1.04M | 1.44M | 2.83M | 20.12M |
Total Non-Current Assets | 404K | 929K | 2.49M | 5.34M | 4.19M | 35.1M | 59.32M | 60.62M | 63.76M | 70.28M |
Property, Plant & Equipment | 276K | 386K | 2.23M | 2.27M | 3.71M | 18.38M | 23.78M | 25.7M | 24.73M | 23.57M |
Fixed Asset Turnover | 3.69x | 0.02x | - | 9.25x | 1.98x | 5.57x | 4.77x | 4.12x | 4.71x | 4.91x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 1.86M | 1.7M | 1.71M | 4.73M | 4.63M |
Long-Term Investments | 0 | 0 | 0 | 2.54M | 0 | 7.39M | 23.43M | 24.57M | 0 | 21.53M |
Other Non-Current Assets | 128K | 543K | 257K | 528K | 472K | 7.47M | 5.72M | 3.03M | 27.43M | 34.36M |
Total Assets | 39.51M▲ 0% | 124.92M▲ 216.1% | 98.55M▼ 21.1% | 94.85M▼ 3.8% | 55.66M▼ 41.3% | 84.75M▲ 52.3% | 116.54M▲ 37.5% | 125.41M▲ 7.6% | 166.13M▲ 32.5% | 162.01M▲ 0% |
Asset Turnover | 0.03x | 0.00x | - | 0.22x | 0.13x | 1.21x | 0.97x | 0.84x | 0.70x | 0.73x |
Asset Growth % | 3.74% | 216.15% | -21.11% | -3.76% | -41.31% | 52.26% | 37.5% | 7.61% | 32.48% | 110.79% |
Total Current Liabilities | 8.74M | 4.8M | 28.9M | 17.8M | 14.16M | 12.24M | 20.05M | 19.52M | 18.29M | 19.79M |
Accounts Payable | 747K | 1.25M | 4.28M | 5.93M | 6.42M | 122K | 355K | 108K | 124K | 265K |
Days Payables Outstanding | 21.22 | 21.21 | 10.7K | 236.26 | 305.47 | 9.29 | 27.95 | 10.15 | 8.36 | 16.13 |
Short-Term Debt | 5.08M | 0 | 483K | 663K | 1.98M | 0 | 0 | 0 | 636K | 751K |
Deferred Revenue (Current) | 212K | 0 | 15M | 1.98M | 230K | 0 | 79K | 156K | 14K | 109K |
Other Current Liabilities | 2.69M | 3.55M | 7.03M | 6.74M | 4.07M | 4.86M | 648K | 5.7M | 14.57M | 18.77M |
Current Ratio | 4.48x | 25.83x | 3.32x | 5.03x | 3.63x | 4.06x | 2.85x | 3.32x | 5.60x | 4.64x |
Quick Ratio | 3.87x | 25.83x | 3.32x | 5.03x | 3.63x | 3.56x | 2.64x | 2.99x | 5.04x | 4.06x |
Cash Conversion Cycle | 138.22 | - | - | - | - | 512.63 | 363.28 | 685.99 | 792.76 | 693.16 |
Total Non-Current Liabilities | 0 | 174K | 1.32M | 981K | 408K | 294K | 82.54M | 7.49M | 5.56M | 5.24M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 72K |
Capital Lease Obligations | 0 | 0 | 1.32M | 981K | 408K | 121K | 199K | 885K | 303K | 1.07M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 174K | 0 | 0 | 0 | 173K | 82.13M | 5.67M | 4.41M | 5.17M |
Total Liabilities | 8.74M | 4.97M | 30.22M | 18.78M | 14.57M | 12.54M | 102.59M | 27M | 23.85M | 25.03M |
Total Debt | 5.08M | 0 | 1.8M | 1.64M | 2.38M | 613K | 409K | 1.6M | 939K | 823K |
Net Debt | -9.39M | -31.21M | -13.57M | -28.72M | -41.96M | -24.56M | -33.1M | -10.21M | -36.13M | -36.68M |
Debt / Equity | 0.17x | - | 0.03x | 0.02x | 0.06x | 0.01x | 0.03x | 0.02x | 0.01x | 0.01x |
Debt / EBITDA | - | - | - | - | - | 0.06x | - | 0.09x | 0.07x | 0.45x |
Net Debt / EBITDA | - | - | - | - | - | -2.38x | - | -0.58x | -2.58x | -19.87x |
Interest Coverage | - | - | - | - | - | - | - | - | - | - |
Total Equity | 30.77M▲ 0% | 119.94M▲ 289.8% | 68.34M▼ 43.0% | 76.07M▲ 11.3% | 41.09M▼ 46.0% | 72.22M▲ 75.8% | 13.95M▼ 80.7% | 98.4M▲ 605.4% | 142.28M▲ 44.6% | 136.99M▲ 0% |
Equity Growth % | 91.49% | 289.76% | -43.03% | 11.32% | -45.98% | 75.76% | -80.68% | 605.44% | 44.59% | 154.14% |
Book Value per Share | 8.99 | 10.70 | 5.69 | 3.97 | 1.34 | 0.95 | 0.21 | 0.96 | 1.38 | 1.50 |
Total Shareholders' Equity | 30.77M | 119.94M | 68.34M | 76.07M | 41.09M | 42.52M | -15.83M | 63.32M | 106.03M | 101.31M |
Common Stock | 6K | 12K | 12K | 22K | 31K | 64K | 77K | 86K | 91 | 91K |
Retained Earnings | -173.49M | -203.34M | -258.52M | -314.76M | -402.69M | 10.05M | -85.54M | -73.45M | -68.43M | -77.67M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | -4K | 34K | 5K | 0 | -392K | 1.45M | 501K | 2.32M | 586K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 29.7M | 29.78M | 35.08M | 36.25M | 35.68M |
GYRE Cash Flow Statement
Gyre Therapeutics, Inc. (GYRE) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -19.94M | -28.55M | -43.61M | -55.05M | -83.75M | 10.68M | 25.89M | -3.64M | 1.01M | 4.32M |
Operating CF Margin % | -1958.74% | -475883.33% | - | -262.78% | -1141.39% | 10.44% | 22.82% | -3.44% | 0.87% | - |
Operating CF Growth % | -7.95% | -43.19% | -52.74% | -26.22% | -52.15% | 112.75% | 142.5% | -114.06% | 127.74% | 2777.37% |
Net Income | -21.56M | -30.05M | -55.18M | -56.24M | -87.93M | 4.31M | -85.48M | 17.9M | 9.88M | -6.29M |
Depreciation & Amortization | 173K | 149K | 146K | 138K | 290K | 1.13M | 1.11M | 1.59M | 2.48M | 2.62M |
Stock-Based Compensation | 863K | 2.61M | 3.2M | 3.63M | 3.4M | 13.37M | 7.28M | 831K | 7.16M | 6.65M |
Deferred Taxes | 0 | 0 | -11.42M | 0 | -3.89M | -838K | -1.16M | -1M | -1.11M | -738K |
Other Non-Cash Items | 18K | 116K | 11.42M | 0 | 3.89M | 503K | 96.68M | -7.27M | -1.84M | 2.06M |
Working Capital Changes | 567K | -1.37M | 8.21M | -2.57M | 483K | -7.8M | 7.46M | -15.69M | -15.55M | -2.69M |
Change in Receivables | 7K | 0 | -15M | 11.69M | 1.5M | -7.92M | 1.3M | -9.29M | -11.95M | -3M |
Change in Inventory | -479K | 0 | -490K | 0 | 3.88M | -879K | 1.75M | -2.14M | -3.63M | -3.1M |
Change in Payables | -90K | 500K | 3.03M | 1.65M | 500K | -112K | 192K | -245K | 13K | 138K |
Cash from Investing | -11.25M | -71.32M | 27.39M | 9.66M | 48.19M | -13.81M | -19.76M | -19.88M | -474K | -5.5M |
Capital Expenditures | -23K | -376K | -64K | -267K | -839K | -4.99M | -8.52M | -2.31M | -1.19M | -1.25M |
CapEx % of Revenue | 2.26% | 6266.67% | - | 1.27% | 11.43% | 4.87% | 7.51% | 2.19% | 1.02% | 1.07% |
Acquisitions | 0 | 0 | -27.46M | 0 | 0 | -1.33M | 4.02M | -1.69M | 30K | 6K |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -57K | -70.94M | 27.46M | 0 | 0 | -13K | 471K | -412K | 686K | -50K |
Cash from Financing | 35.4M | 111.33M | 327K | 60.38M | 49.55M | 0 | 2.5M | 2.1M | 24.38M | 23.05M |
Debt Issued (Net) | -14.32M | -5.08M | 0 | 0 | -6.7M | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 35.4M | 116.41M | 327K | 60.38M | 49.55M | 0 | 2.5M | 773K | 25.86M | 23.34M |
Dividends Paid | -3.95M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 18.27M | 0 | 0 | 0 | 6.7M | 0 | 0 | 1.33M | -1.49M | -284K |
Net Change in Cash | 4.21M▲ 0% | 11.46M▲ 172.3% | -15.89M▼ 238.7% | 14.99M▲ 194.3% | 13.99M▼ 6.7% | -5.03M▼ 135.9% | 8.33M▲ 265.8% | -21.7M▼ 360.3% | 25.26M▲ 216.4% | 22.46M▲ 0% |
Free Cash Flow | -19.96M▲ 0% | -28.93M▼ 44.9% | -43.68M▼ 51.0% | -55.31M▼ 26.6% | -84.59M▼ 52.9% | 5.68M▲ 106.7% | 17.31M▲ 204.7% | -6.77M▼ 139.1% | -180K▲ 97.3% | 3.04M▲ 0% |
FCF Margin % | -1961% | -482150% | - | -264.06% | -1152.82% | 5.55% | 15.25% | -6.4% | -0.15% | 2.59% |
FCF Growth % | -5.4% | -44.91% | -50.98% | -26.65% | -52.93% | 106.71% | 204.74% | -139.11% | 97.34% | 128.8% |
FCF per Share | -5.83 | -2.58 | -3.64 | -2.88 | -2.76 | 0.08 | 0.26 | -0.07 | -0.00 | 0.03 |
FCF Conversion (FCF/Net Income) | 0.92x | 0.95x | 0.79x | 0.99x | 0.95x | 4.64x | -0.28x | -0.30x | 0.20x | -0.48x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 6.35M | 8.52M | 0 | 1.13M |
GYRE Key Ratios
Gyre Therapeutics, Inc. (GYRE) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -92.05% | -39.88% | -58.61% | -76.93% | -150.11% | 4.06% | -215.71% | 21.51% | 4.18% | -4.6% |
Return on Invested Capital (ROIC) | -70.25% | -46.07% | -59.87% | -84.27% | -270.2% | 29.51% | -353.79% | 35.12% | 8.87% | -0.1% |
Gross Margin | -1161.98% | -357800% | - | 56.26% | -4.52% | 95.31% | 95.91% | 96.33% | 95.35% | 95.09% |
Net Margin | -2117.98% | -500916.67% | - | -265.14% | -1198.32% | 2.25% | -81.92% | 11.43% | 4.31% | -5.37% |
Debt / Equity | 0.17x | - | 0.03x | 0.02x | 0.06x | 0.01x | 0.03x | 0.02x | 0.01x | 0.01x |
FCF Conversion | 0.92x | 0.95x | 0.79x | 0.99x | 0.95x | 4.64x | -0.28x | -0.30x | 0.20x | -0.48x |
Revenue Growth | 155.14% | -99.41% | -100% | - | -64.97% | 1293.98% | 10.91% | -6.78% | 10.24% | 16.3% |
Related:GYRE Dividend History·GYRE Revenue History·GYRE Price History·GYRE P/E History·GYRE Financial Ratios·GYRE Institutional Holders
GYRE SEC Filings & Documents
Gyre Therapeutics, Inc. (GYRE) SEC filings — annual & quarterly reports (10-K, 10-Q)
GYRE Frequently Asked Questions
Gyre Therapeutics, Inc. (GYRE) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Gyre Therapeutics, Inc. (GYRE) reported $117.0M in revenue for fiscal year 2025. This represents a 3031% increase from $3.7M in 2004.
Gyre Therapeutics, Inc. (GYRE) grew revenue by 10.2% over the past year. This is steady growth.
Gyre Therapeutics, Inc. (GYRE) reported a net loss of $6.3M for fiscal year 2025.
Dividend & Returns
Gyre Therapeutics, Inc. (GYRE) has a return on equity (ROE) of 4.2%. This is below average, suggesting room for improvement.
Gyre Therapeutics, Inc. (GYRE) generated $3.0M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.